他汀类调脂药物联合普罗布考降低血脂的疗效观察

Observation of the clinical effect of statin lipid-lowering drugs combined probucol on lowering the blood fat

目的观察他汀类调脂药物联合普罗布考降低血脂的临床效果。方法选择2015年3月至2016年9月我院收治的106例血脂异常患者,将其随机分为对照组和观察组,每组53例。两组患者均给予常规治疗,在此基础上,对照组给予阿托伐他汀治疗,观察组给予阿托伐他汀联合普罗布考治疗。观察两组患者血脂指标的改善效果与不良反应发生情况。结果治疗后,两组患者的TC、TG、LDLC水平均低于治疗前,HDLC水平高于治疗前,且观察组TC、TG、LDLC水平分别为(4.81±0.89)、(1.54±0.56)、(2.65±0.13)mmol/L,低于对照组的(5.91±0.69)、(1.81±0.79)、(2.99±0.28)mmol/L;观察组HDLC水平为(1.45±0.56)mmol/L,高于对照组的(1.28±0.69)mmol/L,差异均具有统计学意义(P<0.05)。两组不良反应发生率比较,差异不显著(P>0.05)。结论他汀类调脂药物联合普罗布考降血脂作用良好,值得临床推广使用。

Objective To observe the clinical effects of statin lipid-lowering drugs combined with probucol on lowering the blood fat. Methods From March 2015 to September 2016, 106 cases of patients with dyslipidemia in our hospital were selected and randomly divided into control group and observation group, with 53 cases in each group. The two groups were given routine treatment. On this basis, the control group accepted atorvastatin treatment and the observation group received atorvastatin combined with probucol treatment. The improvement of blood lipid indexes and the incidence of adverse reactions in the two groups were observed. Results After treatment, the levels of TC, TG, LDLC declined and the levels of HDLC rised in the two groups, and the levels of TC, TG, LDLC in the observation group were respectively （4.81±0.89）, （1.54±0.56）, （2.65±0.13） mmol/L, which were significantly lower than （5.91±0.69）, （1.81±0.79）, （2.99±0.28） mmol/L in the control group, the level of HDLC in the observation group was （1.45±0.56） mmol/L, which was significantly higher than （1.28±0.69） mmol/L in the control group, the differences were statistically significant （P〈0.05）; the incidence of adverse reactions in the observation group was not significantly different from that in the control group （P〉0.05）. Conclusion Statin lipid-lowering drugs combined with probucol on lowering the blood fat has a good effect, which is worthy of promotion and application.